Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II, prospective clinical study to evaluate the efficacy and safety of Orelabrutinib combined with Low-Dose Radiotherapy or Rituximab in the treatment of Ocular Adnexal MALT Lymphoma
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University